Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy

被引：1

作者：

Xingguo ZHANGJing MIAO Minwei LI Saiping JIANG Fuqiang HU Yongzhong DU Department of Pharmacythe First Affiliated HospitalSchool of MedicineZhejiang UniversityHangzhou China College of Pharmaceutical SciencesZhejiang UniversityHangzhou China State Key Lab for Diagnosis and Treatment of Infectious DiseasesZhejiang UniversityHangzhou China ^{[1
,1
,1
,3
,1
,2
,2
,1
,310003
,2
,310058
,3
,310003
]}

机构：

来源：

Journal of Zhejiang University(Science B:An International Biomedicine & Biotechnology Journal) | 2008年 / 06期

关键词：

Adefovir dipivoxil(ADV); Solid lipid nanoparticles(SLN); Octadecylamine-fluorescein isothiocynate(ODA-FITC); Hepatitis B virus(HBV);

D O I：

暂无

中图分类号：

R94 [药剂学];

学科分类号：

100602 ; 100702 ;

摘要：

Herein,solid lipid nanoparticles(SLN)were proposed as a new drug delivery system for adefovir dipivoxil(ADV). The octadecylamine-fluorescein isothiocynate(ODA-FITC)was synthesized and used as a fluorescence maker to be incorporated into SLN to investigate the time-dependent cellular uptake of SLN by HepG2.2.15.The SLN of monostearin with ODA-FITC or ADV were prepared by solvent diffusion method in an aqueous system.About 15 wt%drug entrapment efficiency(EE)and 3 wt% drug loading(DL)could be reached in SLN loading ADV.Comparing with free ADV,the inhibitory effects of ADV loaded in SLN on hepatitis B surface antigen(HBsAg),hepatitis B e antigen(HBeAg)and hepatitis B virus(HBV)DNA levels in vitro were significantly enhanced.

引用

页码：506 / 510

页数：5

共 10 条

[1] Studies on oral absorption of stearic acid SLN by a novel fluorometric method [J].

Yuan, Hong ;

Chen, Jian ;

Du, Yong-Zhong ;

Hu, Fu-Qiang ;

Zeng, Su ;

Zhao, Hang-Li .

COLLOIDS AND SURFACES B-BIOINTERFACES, 2007, 58 (02) :157-164

[2] Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B [J].

Dai, Chia-Yen ;

Chuang, Wan-Long ;

Hsieh, Ming-Yen ;

Lee, Li-Po ;

Huang, Jee-Fu ;

Hou, Nai-Jen ;

Lin, Zu-Yau ;

Chen, Shinn-Cherng ;

Hsieh, Ming-Yuh ;

Wang, Liang-Yen ;

Tsai, Jun-Fa ;

Chang, Wen-Yu ;

Yu, Ming-Lung .

ANTIVIRAL RESEARCH, 2007, 75 (02) :146-151

[3] Lipids changes in liver cancer. [J].

Jiang J.T. ;

Xu N. ;

Zhang X.Y. ;

Wu C.P. .

Journal of Zhejiang University SCIENCE B, 2007, 8 (6) :398-409

[4] Nucleotide analogs as novel anti-hepatitis B virus agents [J].

Iyer, RP ;

Padmanabhan, S ;

Zhang, GR ;

Morrey, JD ;

Korba, BE .

CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (05) :520-528

[5]

Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system[J] . Fu-Qiang Hu,Sai-Ping Jiang,Yong-Zhong Du,Hong Yuan,Yi-Qing Ye,Su Zeng.Colloids and Surfaces B: Biointerfaces . 2005 (3)

[6] Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients [J].

Westland, CE ;

Yang, H ;

Delaney, WE ;

Wulfsohn, M ;

Lama, N ;

Gibbs, CS ;

Miller, MD ;

Fry, J ;

Brosgart, CL ;

Schiff, ER ;

Xiong, S .

JOURNAL OF VIRAL HEPATITIS, 2005, 12 (01) :67-73

[7] Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus [J].

Perrillo, R ;

Hann, HW ;

Mutimer, D ;

Willems, B ;

Leung, N ;

Lee, WM ;

Moorat, A ;

Gardner, S ;

Woessner, M ;

Bourne, E ;

Brosgart, CL ;

Schiff, E .

GASTROENTEROLOGY, 2004, 126 (01) :81-90

[8] Agents in clinical development for the treatment of chronic hepatitis B [J].

Raney, AK ;

Hamatake, RK ;

Hong, Z .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (08) :1281-1295

[9] Viral hepatitis B [J].

Lai, CL ;

Ratziu, V ;

Yuen, MF ;

Poynard, T .

LANCET, 2003, 362 (9401) :2089-2094

[10] Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants [J].

Perrillo, R ;

Schiff, E ;

Yoshida, E ;

Statler, A ;

Hirsch, K ;

Wright, T ;

Gutfreund, K ;

Lamy, P ;

Murray, A .

HEPATOLOGY, 2000, 32 (01) :129-134

← 1 →